Private equity firms RA Capital and Hillhouse Capital led a $120m Series D funding round in Cytek Biosciences, a biotechnology company. OrbiMed and LYFE Capital also joined the funding round. The investment will be used to expand Cytek’s global infrastructure, sustain its growing momentum and enable the company to deliver on its robust technology platform. “This most recent investment speaks to our significant contributions to the field of flow cytometry, and to our proven ability to push important, emerging fields of research forward through our innovative technology. We are committed to advancing the scope, reach and capabilities of flow cytometry – and to providing researchers and clinicians around the globe with the tools they need to improve patient treatments," Wenbin Jiang, Cytek Biosciences CEO.